
Tom Wilbur is Director of Public Affairs at PhRMA focusing on federal advocacy priorities including Medicare and intellectual property. Prior to joining PhRMA, Tom worked in politics and on Capitol Hill, most recently responsible for communications and strategy for U.S. Rep. Fred Upton and the House Energy and Commerce Committee. Tom is a proud Michigander and outside of the office enjoys reading, running, hiking, golfing, live music, and spending time with family and friends.
Recent Posts
How does Medicare Part D impact you?

Whether you are a direct beneficiary, a caregiver or simply an American taxpayer, Medicare Part D impacts you. The Medicare Part D program, which was created by the Medicare Modernization Act...
Read More
Open Enrollment: How to find a Medicare plan that meets your needs

Medicare’s annual open enrollment period is right around the corner. In fact, beginning October 15 and running through December 7, newly qualified patients and current Medicare beneficiaries may...
Read More
The latest: What they are saying: Intellectual property protections vital to incentivize ongoing COVID-19 research and development

America’s biopharmaceutical companies are committed to COVID-19 treatment and vaccine research and development (R&D). Reliable IP protections have helped drive innovation and enhance patient...
Read More
Three reasons why repealing the Part D non-interference clause is a bad idea

For more than a decade, Medicare Part D has provided seniors affordable and comprehensive prescription drug coverage. Its unique, market-based structure has kept overall Part D program costs far...
Read More
Why the U.S. biopharmaceutical industry is leading the charge against COVID-19

The rapid spread and impact of COVID-19 has sparked a global race to find effective treatments and preventative vaccines with the U.S. biopharmaceutical industry leading the charge. America’s...
Read More
National Medicare Education Week: The history of Medicare Part D

Today, in honor of National Medicare Education Week, we’ll be taking a quick look back at the history of Medicare, specifically the Medicare Part D prescription drug benefit .
Read More
The latest: What they are saying: Intellectual property protections vital to incentivize ongoing COVID-19 research and development

America’s biopharmaceutical companies are committed to COVID-19 treatment and vaccine research and development (R&D). Reliable IP protections have helped drive innovation and enhance patient...
Read More
How Medicare Part D supports patients

Since 2006, Medicare Part D has offered seniors and people living with disabilities affordable access to life-saving treatments through comprehensive prescription drug coverage. The benefit has...
Read More
The latest: What they are saying: Intellectual property protections vital to incentivize ongoing COVID-19 research and development

America’s biopharmaceutical companies are committed to COVID-19 treatment and vaccine research and development (R&D). Reliable IP protections have helped drive innovation and enhance patient...
Read More
Supporting access to vaccines for Part D beneficiaries

Today, in honor of National Immunization Awareness Month, we’ll take a look at how Medicare Part D supports access to critical vaccines and strengthens public health. Vaccines represent some of...
Read More